ELOX insider filings
Eloxx Pharmaceuticals, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-10-21. Screen ELOX transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 2 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 1.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Germano Geno J — Director | 2 | — | — | 1 |
Recent insider filings — Eloxx Pharmaceuticals, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-21 | 4 | Germano Geno J — Director | Grant/award (A): 13,587 (derivative) @ $0 | EDGAR |
| 2026-10-21 | 3 | Germano Geno J — Director | Holdings only — no transactions reported | EDGAR |
| 2026-06-17 | 4 | Domicilium Real Estate Fund III LP — 10% owner | Other (J): 238,422 · Other (J): 361,578 · Other (J): 238,422 (derivative) · Other (J): 361,578 (derivative) | EDGAR |
| 2026-06-10 | 4 | Webster Stephen W — Director | Grant/award (A): 13,587 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Walts Alan Edmund — Director | Grant/award (A): 8,590 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Aggarwal Sumit — President and CEO, Director | Grant/award (A): 328,833 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Kjellson Nina S — Director | Grant/award (A): 13,587 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Rubin Steven D — Director | Grant/award (A): 4,018 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Domicilium Real Estate Fund III LP — 10% owner | Other (J): 113,636 @ $0 · Other (J): 113,636 (derivative) | EDGAR |
| 2026-05-29 | 4 | Coastlands Capital LP — 10% owner | Other (J): 1,250,000 @ $0 · Other (J): 1,250,000 (derivative) @ $0 | EDGAR |
| 2026-05-08 | 4 | Rubin Steven D — Director | Option exercise (M): 1,875 · Grant/award (A): 179,854 (derivative) @ $0 · Option exercise (M): 1,875 (derivative) @ $0 | EDGAR |
| 2026-05-08 | 4 | Aggarwal Sumit — President and CEO, Director, 10% owner | Option exercise (M): 196,880 @ $0.00 · Grant/award (A): 1,000,000 @ $0 · Option exercise (M): 15,000 · Option exercise (M): 260,946 @ $0.15 · Grant/award (A): 42,790 (derivative) @ $0 · Disposition to issuer (D): 42,790 (derivative) · +14 more | EDGAR |
| 2026-05-08 | 4 | Walts Alan Edmund — Director | Option exercise (M): 1,875 · Grant/award (A): 395,680 (derivative) @ $0 · Option exercise (M): 1,875 (derivative) @ $0 | EDGAR |
| 2025-01-28 | 4 | Aggarwal Sumit — Director | Option exercise (M): 30,000 @ $0 · Option exercise (M): 30,000 (derivative) @ $0 | EDGAR |
| 2025-01-28 | 4 | Rubin Steven D — Director | Option exercise (M): 3,750 @ $0 · Option exercise (M): 3,750 (derivative) @ $0 | EDGAR |
| 2025-01-28 | 4 | Androski Lindsay — Director | Option exercise (M): 3,750 @ $0 · Option exercise (M): 3,750 (derivative) @ $0 | EDGAR |
| 2025-01-28 | 4 | Walts Alan Edmund — Director | Option exercise (M): 3,750 @ $0 · Option exercise (M): 3,750 (derivative) @ $0 | EDGAR |
| 2024-10-17 | 4 | Walts Alan Edmund — Director | Grant/award (A): 12,000 @ $0 | EDGAR |
| 2024-10-17 | 4 | Androski Lindsay — Director | Grant/award (A): 12,000 @ $0 | EDGAR |
| 2024-10-17 | 4 | Rubin Steven D — Director | Grant/award (A): 12,000 @ $0 | EDGAR |
| 2024-10-17 | 4 | Aggarwal Sumit — PRESIDENT AND CEO, Director | Grant/award (A): 165,000 @ $0 | EDGAR |
| 2024-01-26 | 4 | Walts Alan Edmund — Director | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2024-01-26 | 4 | Rubin Steven D — Director | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2024-01-26 | 4 | Androski Lindsay — Director | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2024-01-26 | 4 | Aggarwal Sumit — PRESIDENT AND CEO, Director | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2023-01-31 | 4 | Walts Alan Edmund — Director | Grant/award (A): 2,859 (derivative) @ $0 | EDGAR |
| 2023-01-31 | 4 | Rubin Steven D — Director | Grant/award (A): 2,859 (derivative) @ $0 | EDGAR |
| 2023-01-31 | 4 | Kariv Tomer — Director | Grant/award (A): 2,859 (derivative) @ $0 | EDGAR |
| 2023-01-31 | 4 | Androski Lindsay — Director | Grant/award (A): 2,859 (derivative) @ $0 | EDGAR |
| 2023-01-27 | 4 | Aggarwal Sumit — PRESIDENT AND CEO, Director | Grant/award (A): 68,700 (derivative) @ $0 | EDGAR |
| 2023-01-27 | 4 | MODUR VIJAY — HEAD OF R&D | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2022-07-06 | 4 | Androski Lindsay — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2022-06-17 | 4 | Walts Alan Edmund — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-06-17 | 4 | Veinrib Gadi — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-06-17 | 4 | Seehra Jasbir — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-06-17 | 4 | Rubin Steven D — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-06-17 | 4 | PAREKH RAJESH B — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-06-17 | 4 | Nussbaum Ran — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-06-17 | 4 | Kariv Tomer — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-06-17 | 4 | Avnur Zafrira — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2021-12-03 | 4 | Walts Alan Edmund — Director | Option exercise (M): 37,695 @ $0 · Option exercise (M): 37,695 (derivative) @ $0 | EDGAR |
| 2021-12-03 | 4 | Aggarwal Sumit — PRESIDENT AND CEO, Director | Option exercise (M): 279,158 @ $0 · Tax withholding (F): 81,933 @ $0.72 · Option exercise (M): 279,158 (derivative) @ $0 | EDGAR |
| 2021-12-03 | 4 | MODUR VIJAY — HEAD OF R&D | Option exercise (M): 219,326 @ $0 · Tax withholding (F): 64,373 @ $0.72 · Option exercise (M): 219,326 (derivative) @ $0 | EDGAR |
| 2021-12-01 | 4 | Geffken Daniel E. — INTERIM CFO | Purchase (P): 50,000 @ $0.72 | EDGAR |
| 2021-07-30 | 4 | Belloff Neil S. — COO, GENERAL COUNSEL &CORP SEC | Option exercise (M): 1,563 @ $0 · Tax withholding (F): 459 @ $1.32 · Option exercise (M): 1,563 (derivative) @ $0 | EDGAR |
| 2021-05-26 | 4 | Belloff Neil S. — COO, GENERAL COUNSEL &CORP SEC | Option exercise (M): 6,250 @ $0 · Tax withholding (F): 1,835 @ $1.39 · Option exercise (M): 6,250 (derivative) @ $0 | EDGAR |
| 2021-05-20 | 4 | Kariv Tomer — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2021-05-20 | 4 | Veinrib Gadi — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2021-05-20 | 4 | Seehra Jasbir — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2021-05-20 | 4 | Rubin Steven D — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Eloxx Pharmaceuticals, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-16 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-22 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events | EDGAR |
| 2026-08-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-01 | 8-K | 3.02 — Unregistered Sales of Equity Securities 3.03 — Material Modification to Rights of Security Holders 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-01 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2025-08-12 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-10-17 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-07-16 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | EDGAR |
| 2024-03-29 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2024-03-14 | 8-K | 1.01 — Entry into a Material Definitive Agreement | EDGAR |
Registration filings — Eloxx Pharmaceuticals, Inc.
Securities Act registration lifecycles tracked for this issuer (live-forward since 2026-08-01), threaded by SEC file number.
- SEC file 333-298904 (S-1) — latest: Initial registration (S-1), filed 2026-09-11
GET https://api.filingpulse.io/v1/insider-trades?ticker=ELOX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs